January 28, 2025 06:15 PM ESTUpdated January 29, 06:42 AM

Ahead of earnings, Lilly culls mid-stage drug for heart failure and chronic kidney disease

Kyle LaHucik

Senior Reporter

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ahead of earnings, Lilly culls mid-stage drug for heart failure and chronic kidney disease

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

RFK blog: Republican swing votes question Kennedy's vaccine stances

Takeda CEO Christophe Weber to retire in June 2026, Julie Kim to take over

Roche aims for derisked deals and ruthless portfolio cuts in 2025

Sanofi is in the market for M&A, thanks to ‘strong’ balance sheet

Cargo Therapeutics cuts lead CAR-T program, 50% of staff

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

Ahead of earn­ings, Lil­ly culls mid-stage drug for heart fail­ure and chron­ic kid­ney dis­ease

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ahead of earnings, Lilly culls mid-stage drug for heart failure and chronic kidney disease